Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Revance Reports Efficacy For Botulinum Toxin Type A
Revance Therapeutics’ RT001, a topical botulinum toxin type A, under investigation for the treatment of crow’s feet wrinkles, has demonstrated efficacy and safety in a US phase 2b
Revance Therapeutics’ RT001, a topical botulinum toxin type A, under investigation for the treatment of crow’s feet wrinkles, has demonstrated efficacy and safety in a US phase 2b
Schering-Plough has received marketing approval for Remeron/Reflex (mirtazapine) 15mg tablets, for the treatment of major depressive disorder. The product was developed jointly with Meiji Seika Kabushiki Kaisha. Schering-Plough
Germany-based Bayer Schering Pharma has signed a supply and distribution agreement with the Polish insulin producer, Bioton and its Singapore subsidiary, SciGen, to strengthen its pharmaceutical product portfolio.
Sciele and Victory Pharma have mutually agreed to terminate their previously announced merger agreement, due to the occurrence of an unforeseen development that occurred after the agreement was
Pfizer has reported that it is disappointed by the Canadian Federal Court’s decision declaring its patent covering amlodipine besylate, the active ingredient in Norvasc, as invalid. The company
Osmetech has received FDA 510(k) clearance for its eSensor Cystic Fibrosis Genotyping Test, for use on the eSensor XT-8 System. This multiplex test is used for: cystic fibrosis
Millipore and BioTime’s subsidiary, Embryome Sciences have entered into a co-marketing agreement. Under the agreement, Millipore would become a worldwide distributor of ACTCellerate human progenitor cell lines. Donald
Covidien’ subsidiary, Mallinckrodt is voluntarily recalling one lot of Mallinckrodt Sodium Chromate Cr-51 Injection (lot #370-9004), as a result of routine post-market testing in which the product was
Allon has released top-line results from phase-IIa clinical trial showing that the neuroprotective drug candidate, davunetide intranasal (AL-108), has a positive impact on the ability of schizophrenia patients.
Sciele has reported the availability of Ulesfia (benzyl alcohol) lotion that kills head lice by asphyxiation, without potential neurotoxic side effects. Approved by the FDA, Ulesfia is indicated